MAMMO-50: Mammographic surveillance in breast cancer patients aged 50 years or older

Follow up

SELECT-D: Duration of anticoagulation therapy in SELECTeD patients with advanced cancer at risk of recurrence of venous thromboembolism

Closed

Optima: Optimal Personalised Treatment of breast cancer usIng Multi-parameter Analysis: preliminary study

De-ESCALaTE: Determination of Epidermal growth factor receptor inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus positive oropharyngeal squamous cell carcinoma

Reporting

TEAMM: Tackling Early Morbidity and Mortality in Myeloma

Closed

ARTemis: Avastin Randomised Trial with neo-adjuvant chemotherapy for patients with early breast cancer

PET-NECK: PET-CT guided watch & wait policy versus planned neck dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer

Persephone: Duration of Trastuzumab with chemotherapy in early breast cancer: 6 versus 12 months

LIHNCS: The use of Lugol's Iodine to improve clear resection margin rates in surgery for oral and oropharyngeal carcinoma

Neo-ESCAPE: A trial looking at chemotherapy before and after surgery for advanced peritoneal cancer (Neo-ESCAPE)

AVAST-M: Bevacizumab (Avastin) vs standard observation in patients with resected melanoma at high risk of recurrence

COUGAR-2: Docetaxel vs active symptom control in patients with replapsed gastic adenocarcinoma

MONET: Molecular profiling of postmenopausal women with breast cancer on neoadjuvant exemestane or tamoxifen

PG-SNPS: The pharmacogenetics of early breast cancer chemotherapy (sub-study of NEAT, TANGO and NEO-TANGO)

Can-ETH: Improving ethnic data collection for statistics of cancer incidence, management, mortality, survival in the UK

Neo-Tango: Neoadjuvant study of sequential epirubicin/cyclophosphamide and paclitaxel +/- gemcitabine in the treatment of high risk early breast cancer with molecular profiling, proteomics and candidate gene analysis

VICTOR: Phase III randomised double-blind placebo controlled study of rofecoxib (VIOXX) in colorectal cancer patients following potentially curable therapy

tAnGo: Randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin-based, adjuvant chemotherapy for women with early stage breast cancer

NEAT-SCI-TOPO: National Epirubicin Adjuvant Trial in early breast cancer